EMA Authorised: Myozyme (alglucosidase alfa) — Sanofi B.V.

View source ↗

Summary

EMA authorised marketing of Myozyme (alglucosidase alfa) by Sanofi B.V. for Glycogen storage disease type II (Pompe disease).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Status: Authorised. Therapeutic area: Glycogen Storage Disease Type II. MAH: Sanofi B.V.. Decision date: 14/08/2024